Cargando…

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients

The treatment of infectious complications in cancer patients has evolved as a consequence of the developments in the chemotherapy of cancer patients. In this prospective, randomized study, we compared imipenem-cilastatin and sulbactam-cefoperazone with amikacin in the empiric therapy of febrile neut...

Descripción completa

Detalles Bibliográficos
Autores principales:	ÖZYILKAN, Özgür, YALÇINTAŞ, ÜlKü, BAŞKAN, Sezgin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 1999
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531927/ https://www.ncbi.nlm.nih.gov/pubmed/10461420 http://dx.doi.org/10.3904/kjim.1999.14.2.15

Ejemplares similares

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
por: Tang, Xi-kang, et al.
Publicado: (2022)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
por: Islek, Ismail, et al.
Publicado: (2003)

Cefoperazone-Sulbactam Associated Refractory Seizures
por: Chovatiya, Harshad, et al.
Publicado: (2021)

Cefoperazone/sulbactam-induced hemolytic anemia
por: Sun, XM, et al.
Publicado: (2023)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis
por: Lan, Shao-Huan, et al.
Publicado: (2020)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
por: Sheu, Ming-Jen, et al.
Publicado: (2020)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
por: Zhou, Ling, et al.
Publicado: (2019)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
por: Miao, Wan, et al.
Publicado: (2023)

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam
por: Qu, Yan-Jing, et al.
Publicado: (2016)

Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection
por: Fetiye, Kolayli, et al.
Publicado: (2004)

Case report: Cefoperazone-sulbactam induced Kounis syndrome and cardiogenic shock
por: Ding, Peng, et al.
Publicado: (2022)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review
por: Wang, Zi, et al.
Publicado: (2021)

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature
por: Kogilathota Jagirdhar, Gowthami Sai, et al.
Publicado: (2023)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
por: Wang, Xueting, et al.
Publicado: (2023)

Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy
por: Wang, Qiang, et al.
Publicado: (2015)

Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report
por: Hu, Huan-rong
Publicado: (2019)

Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients
por: Chen, Yue, et al.
Publicado: (2021)

Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease
por: Chao, Chien-Ming, et al.
Publicado: (2022)

Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia
por: Lin, Shang-Yi, et al.
Publicado: (2022)

Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia
por: He, Xiaoyan, et al.
Publicado: (2023)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting cefoperazone/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients
por: Bai, Hehe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4q5d9tgbdkc31auvn3996amcgd